This listing of claims will replace all prior versions of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A crystal of an anti-epidermal growth factor receptor (anti-EGFR) antibody or a variant thereof comprising at least one of

(a) conserved substitution in the antibody amino acid sequence;

(b) glycosylation of one or more amino acid residues;

(c) deglycosylation of one or more amino acid residues; or

(d) PEGylation of one or more amino acid residues;

wherein said antibody or said variant ~~or a fragment thereof which~~ forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said crystal being obtained by a process comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody or a variant thereof ~~or a fragment thereof~~ by means of a precipitation reagent,

wherein said anti-EGFR antibody is a chimeric monoclonal antibody c225 or a humanized monoclonal antibody h425.

Claim 2. (Previously Presented) The crystal according to Claim 1, wherein the precipitation reagent comprises a salt, a polymer, an organic solvent, or a combination thereof.

Claim 3. (Previously Presented) The crystal according to Claim 2, wherein the precipitation reagent comprises ammonium sulfate, sodium acetate, sodium citrate, potassium phosphate, PEG and/or ethanol.

Claim 4. (Canceled)

Claim 5. (Canceled)

Claim 6. (Canceled)

Claim 7. (Canceled)

Claim 8. (Previously Presented) The crystal according to Claim 1, wherein the anti-EGFR antibody is Mab C225 (cetuximab) or Mab h425 (EMD 72000).

Claim 9. (Currently Amended) A process for the preparation of a crystal of an anti-EGFR antibody or a variant thereof comprising at least one of

(a) conserved substitution in the antibody amino acid sequence;

(b) glycosylation of one or more amino acid residues;

(c) deglycosylation of one or more amino acid residues; or

(d) PEGylation of one or more amino acid residues;

wherein said antibody or said variant ~~or a fragment thereof~~ forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said process comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody or ~~a~~ said variant thereof ~~or a fragment thereof~~ by means of a precipitation reagent, and

separating the precipitation product.

Claim 10. (Previously Presented) A process according to Claim 9, wherein the precipitation reagent comprises ammonium sulfate, PEG and/or ethanol.

Claim 11. (Previously Presented) A process according to Claim 9, which is carried out in batch format.

Claim 12. (Previously Presented) A storage-stable medicament which comprises a crystal of claim 1 together with a stabilizing agent.

Claim 13. (Currently Amended) A pharmaceutical preparation which comprises a pharmaceutically acceptable carrier and the crystal according to Claim 1, wherein the anti-EGFR antibody concentration is 50 – 150 mg/ml and said crystal is in crystalline, soluble, or suspended form~~, and a pharmaceutically acceptable carrier~~.

Claim 14. (Cancelled)

Claim 15. (Cancelled)

Claim 16. (Cancelled)

Claim 17. (Withdrawn) A method for the treatment and/or prophylaxis of a tumor or a tumor metastasis in a subject in need thereof, comprising administering to said subject a crystal of claim 1.

Claim 18. (Withdrawn) A method according to Claim 17, wherein the tumor is brain tumor,

tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

Claim 19. (Cancelled)

Claim 20. (Cancelled)

Claim 21. (Previously Presented) The crystal according to Claim 1, wherein the anti-EGFR antibody variant comprises a PEGylated anti-EGFR antibody.

Claim 22. (Previously Presented) The crystal according to Claim 1, which has a size of 50–200 μm.